- Home
- EQX vs SUPN Comparison
EQX vs SUPN Comparison
Compare EQX & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- SUPN
- Stock Information
- Founded
- EQX 2007
- SUPN 2005
- Country
- EQX Canada
- SUPN United States
- Employees
- EQX N/A
- SUPN N/A
- Industry
- EQX Precious Metals
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- SUPN Health Care
- Exchange
- EQX Nasdaq
- SUPN Nasdaq
- Market Cap
- EQX 2.3B
- SUPN 2.1B
- IPO Year
- EQX N/A
- SUPN 2012
- Fundamental
- Price
- EQX $5.84
- SUPN $37.74
- Analyst Decision
- EQX
- SUPN Hold
- Analyst Count
- EQX 0
- SUPN 1
- Target Price
- EQX N/A
- SUPN $36.00
- AVG Volume (30 Days)
- EQX 5.5M
- SUPN 376.5K
- Earning Date
- EQX 02-21-2025
- SUPN 02-25-2025
- Dividend Yield
- EQX N/A
- SUPN N/A
- EPS Growth
- EQX 302.88
- SUPN 130.79
- EPS
- EQX 0.60
- SUPN 1.07
- Revenue
- EQX $1,236,929,000.00
- SUPN $651,972,000.00
- Revenue This Year
- EQX $45.56
- SUPN $7.82
- Revenue Next Year
- EQX $57.70
- SUPN N/A
- P/E Ratio
- EQX $10.88
- SUPN $35.28
- Revenue Growth
- EQX 17.84
- SUPN 6.79
- 52 Week Low
- EQX $3.95
- SUPN $25.53
- 52 Week High
- EQX $6.50
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- EQX 56.46
- SUPN 57.78
- Support Level
- EQX $5.79
- SUPN $36.48
- Resistance Level
- EQX $6.15
- SUPN $38.68
- Average True Range (ATR)
- EQX 0.21
- SUPN 1.06
- MACD
- EQX 0.08
- SUPN 0.09
- Stochastic Oscillator
- EQX 73.87
- SUPN 68.46
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing pipeline of growth projects.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.